Komal Jhaveri
Section Head, Endocrine Therapy Research Program · New York Presbyterian Hospital
Credentials: · · · ·
History
PresentEndocrine Therapy Research Program Section · New York Presbyterian Hospital
- Present
Early Drug Development Service · New York Presbyterian Hospital
- 2004–2007
- 2001–2004
- 1997–2001
Research
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Cancer Cell · 2018 · 814 citations
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer
New England Journal of Medicine · 2023 · 652 citations
HER kinase inhibition in patients with HER2- and HER3-mutant cancers
Nature · 2018 · 645 citations
- EH
23 papers
22 papers
19 papers
- SM
19 papers
16 papers
15 papers
- CH
12 papers
- PR
12 papers · 2 as a fellow
Clinical trials
- 2021–2023
A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer
Principal investigator · Withdrawn · Phase 1
Memorial Sloan Kettering Cancer Center
- 2020–2027
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
Principal investigator · Active not recruiting · Phase 1
AstraZeneca
- 2017–2021
A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer
Principal investigator · Completed · Phase 1, Phase 2
Memorial Sloan Kettering Cancer Center
- 2011–2023
The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies
Principal investigator · Completed · Phase 1
Memorial Sloan Kettering Cancer Center